JP2007510662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510662A5 JP2007510662A5 JP2006538496A JP2006538496A JP2007510662A5 JP 2007510662 A5 JP2007510662 A5 JP 2007510662A5 JP 2006538496 A JP2006538496 A JP 2006538496A JP 2006538496 A JP2006538496 A JP 2006538496A JP 2007510662 A5 JP2007510662 A5 JP 2007510662A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound
- heteroaryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 31
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000923 atherogenic effect Effects 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51705803P | 2003-11-04 | 2003-11-04 | |
| PCT/US2004/036870 WO2005046682A1 (en) | 2003-11-04 | 2004-11-04 | Therapeutic compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510662A JP2007510662A (ja) | 2007-04-26 |
| JP2007510662A5 true JP2007510662A5 (https=) | 2007-11-29 |
Family
ID=34590135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538496A Withdrawn JP2007510662A (ja) | 2003-11-04 | 2004-11-04 | 治療化合物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7504506B2 (https=) |
| EP (1) | EP1682136A4 (https=) |
| JP (1) | JP2007510662A (https=) |
| CN (1) | CN1901908A (https=) |
| CA (1) | CA2544602A1 (https=) |
| MX (1) | MXPA06005038A (https=) |
| WO (1) | WO2005046682A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768041A (zh) | 2003-04-04 | 2006-05-03 | 麦克公司 | 作为黑皮质素－4受体激动剂的酰化螺哌啶衍生物 |
| WO2005097788A2 (en) * | 2004-04-02 | 2005-10-20 | Elixir Pharmaceuticals, Inc. | Sulfonamides and uses thereof |
| US20090275648A1 (en) * | 2005-06-13 | 2009-11-05 | Fraser Graeme L | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| CA2625447C (en) | 2005-09-29 | 2015-06-09 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Compositions and methods for stimulating gastrointestinal motility |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| KR100764640B1 (ko) * | 2006-03-08 | 2007-10-10 | 세원셀론텍(주) | 지방조직 수복용 키트 |
| DE602007006990D1 (de) | 2006-12-07 | 2010-07-15 | Hoffmann La Roche | Spiropiperidinderivate als antagonisten des via-rezeptors |
| BRPI0721138A2 (pt) | 2006-12-22 | 2014-04-01 | Hoffmann La Roche | Derivados de espiro-piperidina |
| CN101583615B (zh) * | 2007-01-12 | 2012-07-04 | 弗·哈夫曼-拉罗切有限公司 | 螺哌啶甘氨酰胺衍生物 |
| CN101657436A (zh) | 2007-02-09 | 2010-02-24 | 特兰齐姆制药公司 | 大环生长素释放肽受体调节剂及其使用方法 |
| US20100022572A1 (en) | 2008-07-18 | 2010-01-28 | Kowa Company, Ltd. | Novel spiro compound and medicine comprising the same |
| CN102224254A (zh) * | 2008-09-23 | 2011-10-19 | 哈佛大学校长及研究员协会 | Sirt4及其用途 |
| JP5477973B2 (ja) | 2008-10-29 | 2014-04-23 | 興和株式会社 | １，２−ジアゼチジン−３−オン誘導体及びこれを含有する医薬 |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| EP2493910A1 (en) | 2009-10-30 | 2012-09-05 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| US20170065678A1 (en) * | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| WO2019123427A1 (en) | 2017-12-22 | 2019-06-27 | Novartis Ag | Methods of treating metabolic disorders with fgf21 variants |
| WO2022066678A1 (en) * | 2020-09-23 | 2022-03-31 | Translate Bio, Inc. | Tes-based cationic lipids |
| EP4282867A1 (en) * | 2021-04-25 | 2023-11-29 | Changchun Genescience Pharmaceutical Co., Ltd. | Indoline-containing spiro derivative, preparation method therefor and application thereof in medicine |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| TW202423413A (zh) * | 2022-10-21 | 2024-06-16 | 大陸商長春金賽藥業有限責任公司 | 吲哚啉螺環類化合物的溶劑化物及其晶型、製備方法和用途 |
| CN119968381A (zh) * | 2022-10-21 | 2025-05-09 | 长春金赛药业有限责任公司 | 吲哚啉螺环类化合物的晶型、无定形物及二者的制备方法和应用 |
| WO2025231012A1 (en) * | 2024-04-29 | 2025-11-06 | Lumos Pharma, Inc. | Piperidine compounds and pharmaceutical compositions |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013696A1 (en) | 1992-12-11 | 1994-06-23 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
| US5492920A (en) | 1993-12-10 | 1996-02-20 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5721251A (en) | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5721250A (en) | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| AU3128195A (en) | 1994-07-20 | 1996-02-16 | Merck & Co., Inc. | Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone |
| US5559128A (en) | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
| EA199800337A1 (ru) * | 1995-10-27 | 1998-10-29 | Мерк Энд Ко., Инк. | Способ получения гормона роста, усиливающего секрецию |
| US5767124A (en) | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
| WO1997022367A1 (en) | 1995-12-20 | 1997-06-26 | Merck & Co., Inc. | Radiolabeled growth hormone secretagogue |
| GB9612276D0 (en) | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| EP1200432B1 (en) | 1999-07-13 | 2004-05-12 | Merck & Co., Inc. | Amido spiropiperidines promote the release of growth hormone |
| WO2005097788A2 (en) * | 2004-04-02 | 2005-10-20 | Elixir Pharmaceuticals, Inc. | Sulfonamides and uses thereof |
-
2004
- 2004-11-04 US US10/982,997 patent/US7504506B2/en not_active Expired - Fee Related
- 2004-11-04 EP EP04800764A patent/EP1682136A4/en not_active Withdrawn
- 2004-11-04 WO PCT/US2004/036870 patent/WO2005046682A1/en not_active Ceased
- 2004-11-04 JP JP2006538496A patent/JP2007510662A/ja not_active Withdrawn
- 2004-11-04 CA CA002544602A patent/CA2544602A1/en not_active Abandoned
- 2004-11-04 MX MXPA06005038A patent/MXPA06005038A/es not_active Application Discontinuation
- 2004-11-04 CN CNA2004800397133A patent/CN1901908A/zh active Pending
-
2009
- 2009-02-09 US US12/367,585 patent/US7897765B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007510662A5 (https=) | ||
| JP2008525416A5 (https=) | ||
| JP2005507872A5 (https=) | ||
| EP1325921A3 (en) | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | |
| JP2007534702A5 (https=) | ||
| JP2009533410A5 (https=) | ||
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| JP2004532266A5 (https=) | ||
| JP2007508359A5 (https=) | ||
| JP2008526724A5 (https=) | ||
| JP2005053931A5 (https=) | ||
| JP2010526814A5 (https=) | ||
| JP2002513793A5 (https=) | ||
| JP2009534468A5 (https=) | ||
| JP2007519721A5 (https=) | ||
| JP2011513305A5 (https=) | ||
| JP2010523476A5 (https=) | ||
| JP2008505117A5 (https=) | ||
| JP2005112864A5 (https=) | ||
| JP2005539088A5 (https=) | ||
| JP2006509015A5 (https=) | ||
| NO20053211L (no) | Forbindelser for behandling av metabolske forstyrrelser. | |
| JP2007531739A5 (https=) | ||
| JP2007527909A5 (https=) | ||
| JP2011516511A5 (https=) |